{"id":4007,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluvoxamine-maleate-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fluvoxamine-maleate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluvoxamine-maleate-txt\/","title":{"rendered":"Fluvoxamine maleate.txt"},"content":{"rendered":"

Fluvoxamine maleate <\/h1>\n

CLINICAL USE <\/H3>
\nSSRI antidepressant:Depression Obsessive compulsive disorder

DOSE IN NORMAL RENAL FUNCTION <\/H3>50\u2013300 mg daily (doses over 150 mg in divided doses)Depression: usual maintenance dose 100 mg dailyObsessive compulsive disorder: usual maintenance dose 100\u2013300 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :434.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :80<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :25<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :13\u201315\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function10\u201330 Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function but titrate slowly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of bleeding with aspirin and NSAIDs; possibly increased concentration of methadone; increased risk of CNS toxicity with tramadol\n
  • Anti-arrhythmics: increased risk of toxicity with mexiletine\n
  • Anticoagulants: effect of coumarins possibly enhanced\n
  • Antidepressants: avoid concomitant use with reboxetine, MAOIs, moclobemide and St John\u2019s wort; possibly enhanced serotonergic effects with duloxetine, fluvoxamine inhibits metabolism of duloxetine \u2013 avoid concomitant use; can increase tricyclics concentration; increased agitation and nausea with tryptophan\n
  • Anti-epileptics: antagonise anticonvulsant threshold; concentration of carbamazepine and phenytoin increased\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: plasma concentration of clozapine and olanzapine increased\n
  • Antivirals: plasma concentration possibly increased by ritonavir\n
  • Ciclosporin: may increase ciclosporin concentration\n
  • Dopaminergics: increased risk of CNS toxicity with rasagiline; hypertension and CNS excitation with selegiline \u2013 avoid concomitant use5HT 1 agonist: risk of CNS toxicity increased with sumatriptan; possibly increased risk of serotonergic effects with frovatriptan; inhibits metabolism of frovatriptan; possibly inhibits metabolism of zolmitriptan \u2013 reduce zolmitriptan doseLinezolid: use with care, possibly increased risk of side effects\n
  • Lithium: increased risk of CNS effects \u2013 monitor levels\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant useTheophylline: increased theophylline concentrations \u2013 avoid concomitant use; if not possible, halve theophylline dose and monitor levels

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>
    \n","protected":false},"excerpt":{"rendered":"

    Fluvoxamine maleate CLINICAL USE SSRI antidepressant:Depression Obsessive compulsive disorder DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4007","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4007"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4007\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}